Table 3.
Indication | Phase of development | Ongoing trials? |
---|---|---|
MDS | Phase 2 (high risk), phase 3 (low risk) | Yes |
MF | Phase 3 | Yes |
ET | Phase 2 | No |
MM | Phase 2, limited by clinical hold | No |
AML | Phase 2 | Yes |
Lymphoid malignancies | Planned | No |
MM, multiple myeloma.